Assertio Holdings Completes Merger with Zydus Lifesciences
Assertio Holdings finalized its acquisition by Zydus Lifesciences, triggering key provisions for its 2027 convertible senior notes.
Assertio Holdings, Inc. has completed its merger with India-based pharmaceutical giant Zydus Lifesciences Ltd., the Lake Forest, Illinois company announced, marking the end of Assertio's run as an independent Nasdaq-listed specialty pharmaceutical firm. The deal, governed by a merger agreement signed May 13, 2026, was executed through Zydus Worldwide DMCC, a Zydus affiliate incorporated in the United Arab Emirates, underscoring the cross-border complexity of the transaction.
The completion of the merger carries immediate and significant financial consequences for holders of Assertio's outstanding 6.50% Convertible Senior Notes due 2027. Under the terms governing those notes, the closing of the deal constitutes both a Fundamental Change and a Make-Whole Fundamental Change — two distinct legal triggers that typically afford noteholders specific rights, including the ability to require repurchase of their notes or to convert them at adjusted rates designed to compensate for the loss of future optionality.
Read more RealTime Reservation Acquires STAY to Build Global Guest Platform →
For debt investors, these provisions are a standard but critical protection mechanism embedded in convertible note indentures. A Fundamental Change clause is designed to shield bondholders when a company undergoes a transformative ownership shift — precisely the kind of event that can alter the credit profile and conversion dynamics that made the notes attractive in the first place. The Make-Whole adjustment layer adds further nuance, offering additional conversion value to noteholders who act during a defined window following the trigger event.
The merger represents a significant expansion move for Zydus Lifesciences, one of India's largest pharmaceutical manufacturers, into the U.S. specialty drug market where Assertio has maintained a commercial presence. For Assertio shareholders, the deal's closure means the company's common stock is no longer traded on Nasdaq as an independent entity. The longer-term strategic rationale — combining Zydus's manufacturing scale with Assertio's U.S. commercial infrastructure — reflects a broader trend of emerging-market pharma firms pursuing direct U.S. market access through acquisition rather than partnership.
Continue reading at BusinessWire.
